April 16th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Considering Targeted Therapies When Managing Young Patients With mCRC
March 27th 2023In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.
Read More
The Expanding Role of the Gut Microbiome in CRC
February 24th 2023Encouraging results in melanoma have led experts to explore the gut microbiome in colorectal cancer. The next hot topic in research may be the gut microbiome's role for the prevention, progression, and management of colorectal cancer.
Read More
Durable Response Seen With PD-1 Plus BRAF/MEK Inhibitor Combo in CRC
February 7th 2023Results of a study of dabrefenib, trametinib, and spartalizumab showed efficacy for the combination of a BRAF inhibitor, a MEK inhibitor, and an anti–PD-1 agent in patients with BRAF V600-mutated colorectal cancer.
Read More
Botensilimab/Balstilimab Combo Shows Potential for MSS CRC
January 31st 2023In an interview with Targeted Oncology, Benjamin Schlechter, MD, FACS, discussed the background of a phase 1a/1b trial in microsatellite stable colorectal cancer and how these findings will influence future research.
Read More
Premarket Approval Submitted for Noninvasive CRC Screening Test
January 26th 2023Results from the CRC-PREVENT trial of a noninvasive diagnostic screening test have led to the submission of a premarket approval application to the FDA for patients with colorectal cancer and advanced adenomas.
Read More
MOUNTAINEER-03 Aims to Confirm Efficacy of Tucatinib/ Trastuzumab/mFOLFOX6 in mCRC
January 23rd 2023In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, FACP, discussed the methods and design of the MOUNTAINEER-03 trial and its role following the positive data observed from MOUNTAINEER.
Read More
brPROPHET May Better Detect ctDNA and Identify MRD in Colorectal Cancer
January 23rd 2023According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.
Read More
ctDNA Serves as Biomarker for Early Response Assessment in Advanced CRC
January 23rd 2023Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.
Read More
Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC
January 21st 2023The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.
Read More
RRx-001 Plus Irinotecan Improves Efficacy vs Regorafenib in Colorectal Cancer
January 13th 2023Findings from the phase 2 ROCKET trial showed a benefit in progression-free survival, overall survival, and overall response rate in patients with colorectal cancer treated with RRx-001 plus irinotecan.
Read More
Gut Microbiome Shows Potential as New Option for Patients With Colorectal Cancer
January 11th 2023In an interview with Targeted Oncology, Patrick Wagner, MD, FACS, discussed the possibility of using the gut microbiome for patients with colorectal cancer, as well as his own research on the topic.
Read More
Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer
September 11th 2022At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.
Read More